Abstract
BACKGROUND: Gastric cancer is the fifth most common cancer worldwide. One of the chemotherapy agents, taxanes is important in increasing patients' survival. The purpose of this study is to assess the efficacy of taxane-based drugs versus non-taxanes in neoadjuvant chemotherapy in non-metastatic gastric adenocarcinoma (GA) in Iranian patients. MATERIALS AND METHODS: In a historical cohort method, 65 patients between 18 and 75 years old who suffered from non-metastatic GA were included. Nineteen and 21 and 25 patients, had undergone DCF (docetaxel, cisplatin, 5fluorouracil) and FLOT (5fluorouracil, leucovorin, oxaliplatin, docetaxel) and FOLFOX6 (oxaliplatin, leucovorin, 5fluorouracil) regimens, respectively, between 2018 and 2021. Survival criteria consisting of progression-free survival (PFS), overall survival (OS), progression rate, and mortality rate were evaluated using the Kaplan–Meier method, in a three-year follow-up period. RESULTS: The majority of patients were male (72.3%), with a median age of 65 years. Most of the patients had lesions with tumor, node, metastasis (TNM) stage IIIb (27.7%) and poor differentiated pathological grade (49.2%). OS time had a significant correlation with the low TNM stage ( P = 0.01), well-differentiated pathological grade ( P = 0.005), and FLOT vs. FOLFOX protocol (20.3 vs. 12.2 months, respectively. P =0.04). FLOT regimen had significantly better OS survival vs. DCF regimen (20.3 vs. 15.4 months, respectively, P = 0.03). No significant correlation was observed between survival criteria and other factors like gender, age, past medical history, Karnofsky scale, and tumor location in the stomach. The taxane-based arm (sum of DSF and FLOT) had no superiority over the non-taxane arm in survival criteria. CONCLUSION: FLOT protocol, as a taxane-based regimen had better survival compared to FOLFOX protocol in neoadjuvant chemotherapy in gastric non-metastatic adenocarcinoma.
Keywords
Subject
Publication details
- DOI
- 10.4103/jehp.jehp_786_22
- Journal
- Journal of Education and Health Promotion, 12(1), 205
- Publisher
- Wolters Kluwer Medknow Publications
- Open access
- Gold open access
- License
- CC BY-NC-SA 4.0
Cite this article
APA 7
Kianersi, S., Salari, S., Rezvani, H., Araskhan, M. A., Shirangi, A., Fathi, M. R., & Ghorbi, M. D. (2023). Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer. Journal of Education and Health Promotion, 12(1), 205. https://doi.org/10.4103/jehp.jehp_786_22
MLA 9
Kianersi, Shirin, et al. "Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer." Journal of Education and Health Promotion, vol. 12, no. 1, 2023, pp. 205. https://doi.org/10.4103/jehp.jehp_786_22.
Chicago (author–date)
Kianersi, Shirin, Sina Salari, Hamid Rezvani, Mohammad A. Araskhan, Alireza Shirangi, Mohammad R. Fathi, and Mahmoud Dehghani Ghorbi. 2023. "Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer." Journal of Education and Health Promotion 12 (1): 205. https://doi.org/10.4103/jehp.jehp_786_22.
Harvard
Kianersi, S., Salari, S., Rezvani, H., Araskhan, M. A., Shirangi, A., Fathi, M. R. and Ghorbi, M. D. (2023) 'Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer', Journal of Education and Health Promotion, 12(1), pp. 205. doi:10.4103/jehp.jehp_786_22.
Vancouver
Kianersi S, Salari S, Rezvani H, Araskhan MA, Shirangi A, Fathi MR, et al. Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer. Journal of Education and Health Promotion. 2023;12(1):205. doi:10.4103/jehp.jehp_786_22
IEEE
S. Kianersi, S. Salari, H. Rezvani, M. A. Araskhan, A. Shirangi, M. R. Fathi, and M. D. Ghorbi, "Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer," Journal of Education and Health Promotion, vol. 12, no. 1, pp. 205, 2023, doi: 10.4103/jehp.jehp_786_22.